IMAGE: Dr. David Cachia is leading MUSC Hollings Cancer Center’s portion of a national study to help understand how cancer patients who also contract COVID-19 are impacted long-term. view more
Credit: MUSC Hollings Cancer Center
Researchers at MUSC Hollings Cancer Center have joined a nationwide study to look at the long-term outcomes of cancer patients who have been diagnosed with COVID-19.
The study, which is led by the National Cancer Institute (NCI) and involves the participation of cancer centers across the country, hopes to answer critical questions about how the two diseases intersect, including how often COVID-19 is diagnosed in people with cancer, how COVID-19 impacts cancer treatments and whether the risk of serious illness from COVID-19 is higher in certain cancer subtypes.
While evidence suggests that people who are undergoing cancer treatment are likely at a higher risk of developing a more severe form of COVID-19, little is known about the factors that may make certain patients more prone to COVID-19 infection or how the disease impacts cancer outcomes after a patient has recovered.
According to David Cachia, M.D., a neuro-oncologist at Hollings and the principal investigator for Hollings’ portion of the study, the data being collected will help providers make more informed decisions
Article originally posted at